# Skin Cancer And Radiotherapy Review

Dr. Jordan Stosky, MD, FRCPC, DABR

Radiation Oncology Review Course

October 18, 2022

# Disclosures

- I am not paid by ‘big melanoma’
  - Only ’big AHS’
- No outside funding to disclose

# We have 1 hour

- What this is:
  - A basic science and anatomy refresher as it pertains to skin cancer and radiotherapy
  - An overview of *some* of the literature supporting and guiding treatment decisions in the use of radiotherapy in skin cancers
- What this is not:
  - A complete review of systemic agents and their use in skin cancers
    - Eg immunotherapy, targeted therapies
  - An exhaustive treatment planning compendium

# Objectives

01

Review UV Radiobiology

02

Review Melanoma and Radiotherapy

03

Review BCC and SCC and Radiotherapy

04

Review Merkel Cell Carcinoma and Radiotherapy

05

Anatomy Refresher



# UV carcinogenesis

# UV Radiation is:



A) IONIZING

B) NON-IONIZING

# UV Spectrum


X rays
Deeper penetration
UVC
UVB
UVA
100-280
280-310
310-400
Visible
Superficial penetration

# UV radiation – chemical reaction

- >=10 eV or λ <=125nm is ionizing ('far' ultraviolet)
- Most UV radiation non ionizing (UV B)
- Forms pyrimidine dimers (T-T) which are cytotoxic
- UVB thought to be the cause of melanoma and other skin cancers
- UVA cause skin cancers and premature aging of skin

**Table 27.3 Lesions Produced for a Given Level of Cell Killing by Various Cytotoxic Agents**

| AGENT | $D_{37}$ | DNA LESION | NUMBER OF LESIONS PER CELL PER $D_{37}$ |
|---|---|---|---|
| X-rays | 1 Gy | SSB | 1,000 |
| | | DSB | 40 |
| Bleomycin | 5.5 μg × 1 h | SSB | 150 |
| | | DSB | 30 |
| Ultraviolet light | 10 $J/m^2$ | TT dimer | 1,000,000 |
| | | SSB | 100 |
| Benzopyrene | – | Adduct | 100,000 |

SSB, single-strand break; DSB, double-strand break; TT, thymine-thymine.
Courtesy of Dr. John Ward, University of California, San Francisco.

# UV Carcinogenesis



# UV induced immunosuppression




I
II
III
IV
V
VI
Pigmentary phototype
(Fitzpatrick scale)
Epidermal Melanin
UV phenotype
UV sensitive,
Burn rather than tan
UV resistant,
Tan; never burn
Cancer risk

# Skin types



# Melanoma

Always on your differential diagnosis

**Table 1: Projected estimates of new cases and age-standardized incidence rates for cancers in Canada in 2020, by sex**

| | No. of new cases | | | ASIR* | | |
|---|---|---|---|---|---|---|
| Type of cancer | Total† | Males | Females | In both sexes | Males | Females |
| **All cancers‡** | 225 800 | 115 800 | 110 000 | 519.4 | 557.8 | 491.2 |
| Lung and bronchus | 29 800 | 15 000 | 14 800 | 61.4 | 64.8 | 59.3 |
| Breast | 27 700 | 240 | 27 400 | 66.9 | 1.1 | 128.2 |
| Colorectal | 26 900 | 14 900 | 12 000 | 60.5 | 71.5 | 50.8 |
| Prostate | 23 300 | 23 300 | NA | NA | 116.7 | NA |
| Bladder§ | 12 200 | 9400 | 2800 | 25.0 | 42.0 | 10.7 |
| Non-Hodgkin lymphoma | 10 400 | 5800 | 4500 | 24.4 | 29.3 | 20.2 |
| Thyroid | 8600 | 2300 | 6400 | 22.5 | 11.7 | 33.1 |
| Melanoma | 8000 | 4400 | 3600 | 21.8 | 25.2 | 19.2 |
| Kidney and renal pelvis | 7500 | 4900 | 2600 | 17.3 | 23.6 | 11.5 |
| Uterus (body, NOS) | 7400 | NA | 7400 | NA | NA | 35.0 |
| Leukemia | 6900 | 4100 | 2800 | 16.5 | 21.1 | 12.6 |
| Pancreas | 6000 | 3100 | 2900 | 13.0 | 14.2 | 11.8 |
| Oral | 5400 | 3700 | 1650 | 12.8 | 18.5 | 7.5 |
| Stomach | 4200 | 2700 | 1450 | 9.4 | 13.1 | 6.1 |
| Multiple myeloma | 3400 | 2000 | 1450 | 7.8 | 9.7 | 6.1 |
| Ovary | 3100 | NA | 3100 | NA | NA | 14.2 |
| Liver | 3100 | 2300 | 810 | 6.8 | 10.6 | 3.3 |
| Brain/CNS | 3000 | 1700 | 1350 | 7.1 | 8.3 | 5.9 |
| Esophagus | 2400 | 1850 | 550 | 5.7 | 9.3 | 2.4 |
| Cervix | 1350 | NA | 1350 | NA | NA | 7.1 |
| Testis | 1150 | 1150 | NA | NA | 6.5 | NA |
| Larynx | 1150 | 980 | 180 | 2.3 | 4.1 | 0.7 |
| Hodgkin lymphoma | 1000 | 570 | 440 | 2.6 | 2.9 | 2.3 |
| All other cancers | 21 800 | 11 300 | 10 500 | 47.5 | 53.2 | 43.2 |

Note: ASIR = age-standardized incidence rate, CNS = central nervous system, NOS = not otherwise specified, NA = not applicable.
*Rates exclude those from Quebec.
†Column total may not sum to row totals owing to rounding.
‡All cancers excludes nonmelanoma skin cancers (neoplasms, NOS; epithelial neoplasms, NOS; and basal and squamous).
§Bladder cancer includes in situ carcinomas.



**Table 2: Projected estimates of deaths and age-standardized mortality rates for cancers in Canada in 2020, by sex**

| | No. of deaths | | | ASMR | | |
|---|---|---|---|---|---|---|
| Type of cancer | Total* | Males | Females | Both sexes | Males | Females |
| **All cancers** | 83 300 | 44 100 | 39 300 | 188 | 219.7 | 164.2 |
| Lung and bronchus | 21 200 | 11 000 | 10 200 | 47.2 | 53.4 | 42.5 |
| Colorectal | 9700 | 5300 | 4400 | 21.8 | 26.4 | 18.0 |
| Pancreas | 5300 | 2700 | 2600 | 12.0 | 13.5 | 10.7 |
| Breast | 5100 | 55 | 5100 | 11.9 | 0.3 | 22.0 |
| Prostate | 4200 | 4200 | NA | NA | 21.8 | NA |
| Leukemia | 3000 | 1800 | 1250 | 6.9 | 9.0 | 5.2 |
| Non-Hodgkin lymphoma | 2900 | 1600 | 1250 | 6.5 | 8.1 | 5.1 |
| Bladder | 2600 | 1850 | 720 | 5.7 | 9.6 | 2.8 |
| Brain/CNS | 2500 | 1400 | 1050 | 5.8 | 7.1 | 4.7 |
| Esophagus | 2300 | 1750 | 510 | 5.1 | 8.6 | 2.1 |
| Ovary | 1950 | NA | 1950 | NA | NA | 8.3 |
| Stomach | 1950 | 1200 | 760 | 4.5 | 6.0 | 3.2 |
| Kidney and renal pelvis | 1950 | 1300 | 680 | 4.4 | 6.4 | 2.8 |
| Multiple myeloma | 1600 | 880 | 700 | 3.5 | 4.4 | 2.8 |
| Oral | 1500 | 1050 | 440 | 3.5 | 5.3 | 1.8 |
| Liver† | 1450 | 1150 | 290 | 3.2 | 5.5 | 1.2 |
| Uterus (body, NOS) | 1300 | NA | 1300 | NA | NA | 5.4 |
| Melanoma | 1300 | 870 | 450 | 3.1 | 4.4 | 2.0 |
| Cervix | 410 | NA | 410 | NA | NA | 2.0 |
| Larynx | 400 | 330 | 75 | 0.9 | 1.6 | 0.3 |
| Thyroid | 230 | 110 | 130 | 0.5 | 0.5 | 0.5 |
| Hodgkin lymphoma | 100 | 65 | 40 | 0.2 | 0.3 | 0.2 |
| Testis | 35 | 35 | NA | NA | 0.2 | NA |
| All other cancers | 10 400 | 5400 | 5000 | 23.5 | 27.3 | 20.5 |

Note: ASMR = age-standardized mortality rate, CNS = central nervous system, ICD-10 = *International Statistical Classification of Diseases and Related Health Problems, 10th Revision*, NA = not applicable, NOS = not otherwise specified.
*Column total may not sum to row totals owing to rounding.
†Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9) were excluded.

## Summary of projected number of cancer cases and deaths in Alberta (AB) in 2020*

| Cancer | Males | | Females | | Both sexes | |
|---|---|---|---|---|---|---|
| | Cases | Deaths | Cases | Deaths | Cases | Deaths |
| **All cancers** | **11,200** | **3,800** | **10,100** | **3,400** | **21,300** | **7,200** |
| Prostate | 3,000 | 440 | N/A | N/A | 3000 | 440 |
| Breast | 15 | 5 | 2,800 | 480 | 2,815 | 485 |
| Colorectal | 1,450 | 460 | 1,100 | 330 | 2,550 | 790 |
| Lung and bronchus (lung) | 1,150 | 850 | 1,250 | 890 | 2,400 | 1,740 |
| Bladder | 800 | 160 | 220 | 55 | 1,020 | 215 |
| Non-Hodgkin lymphoma | 520 | 130 | 390 | 95 | 910 | 225 |
| Melanoma | 390 | 70 | 350 | 45 | 740 | 115 |
| Uterus (body, NOS) | N/A | N/A | 750 | 110 | 750 | 110 |
| Leukemia | 440 | 140 | 290 | 100 | 730 | 240 |
| Kidney and renal pelvis | 480 | 110 | 230 | 55 | 710 | 165 |
| Thyroid | 200 | 15 | 500 | 10 | 700 | 25 |
| Pancreas | 280 | 240 | 270 | 250 | 550 | 490 |
| Oral | 360 | 80 | 140 | 35 | 500 | 115 |
| Brain/CNS | 170 | 140 | 130 | 90 | 300 | 230 |
| Multiple myeloma | 190 | 75 | 110 | 60 | 300 | 135 |
| Stomach | 190 | 95 | 110 | 65 | 300 | 160 |
| Esophagus | 240 | 210 | 50 | 50 | 290 | 260 |
| Liver | 190 | 100 | 75 | 30 | 265 | 130 |
| Ovary | N/A | N/A | 240 | 170 | 240 | 170 |
| Cervical | N/A | N/A | 170 | 40 | 170 | 40 |
| Testis | 160 | 5 | N/A | N/A | 160 | 5 |
| Hodgkin lymphoma | 70 | 5 | 40 | 5 | 110 | 10 |
| Larynx | 75 | 35 | 10 | 5 | 85 | 40 |

# Melanoma Risk factors

- UVB
  - Greatest increase in RR in people who experience blistering sunburns
- Fair complexion
- Numerous benign or larger atypical nevi (>5mm)
  - 15% of melanomas are from melanocytic nevi
  - <10% are from non cutaneous sites. Commonly:
    - Mucosal
    - Uveal
    - Gyne areas
- Personal hx (HR 900)
- Family hx

# Don’t forget your ABCDEs



# Melanoma Genetics

- 10% familial with mutations in:
  - CDKN2A
  - CDK4
  - XP
  - BRCA2
- Familial atypical multiple mole-melanoma syndrome (FAMMM)
- CDKN2A mutation in >70% of lesions
- BRAF mutations
  - Younger, male patients
  - Tends to be more aggressive
  - 40-60% in advance disease

# Normal Skin histology




**Clark's levels**

1. Confined to epidermis (in situ)
2. Invasion into papillary dermis
3. Invasion to junction of papillary and reticular dermis
4. Invasion into reticular dermis
5. Invasion into subcutaneous fat

# Staging and Prognosis

| N Category | Number of tumor-involved regional lymph nodes | Presence of in-transit, satellite and/or microsatellite metastases | T Category | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | T0 | T1a | T1b | T2a | T2b | T3a | T3b | T4a | T4b |
| | | | No evidence of primary tumor | <0.8 mm without ulceration | <0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration | >1.0-2.0 mm without ulceration | >1.0-2.0 mm with ulceration | >2.0-4.0 mm without ulceration | >2.0-4.0 mm with ulceration | >4.0 mm without ulceration | >4.0 mm with ulceration |
| N0 | No regional metastases detected | No | - | IA | IA | IB | IIA | IIA | IIB | IIB | IIC |
| N1a | 1 clinically occult (i.e., detected by SLN biopsy) | No | - | IIIA | IIIA | IIIA | IIIB | IIIB | IIIC | IIIC | IIIC |
| N1b | 1 clinically detected | No | IIIB | IIIB | IIIB | IIIB | IIIB | IIIB | IIIC | IIIC | IIIC |
| N1c | No regional lymph node disease | Yes | IIIB | IIIB | IIIB | IIIB | IIIB | IIIB | IIIC | IIIC | IIIC |
| N2a | 2 or 3 clinically occult (i.e., detected by SLN biopsy) | No | - | IIIA | IIIA | IIIA | IIIB | IIIB | IIIC | IIIC | IIIC |
| N2b | 2 or 3, at least 1 of which was clinically detected | No | IIIC | IIIB | IIIB | IIIB | IIIB | IIIB | IIIC | IIIC | IIIC |
| N2c | 1 clinically occult or clinically detected | Yes | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC |
| N3a | ≥4 clinically occult (i.e., detected by SLN biopsy) | No | - | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIID |
| N3b | ≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes | No | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIID |
| N3c | ≥2 clinically occult or clinically detected and/or presence of any number of matted nodes | Yes | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIIC | IIID |

**T0** — no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma); **Tis** — melanoma in situ;
**Tx** — thickness cannot be assessed. (Tis and Tx are not included in the table but are part of the staging system.)
**Nx** — Regional nodes not assessed (e.g., SLN biopsy not performed, regional nodes previously removed for another reason).
**Exception**: pathological N category is not required for T1 melanomas, use clinical N information. (If an SLNB was performed, the results can and *should* be used for pathological evaluation.)

| T Category | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| T0 | T1a | T1b | T2a | T2b | T3a | T3b | T4a | T4b |
| No evidence of primary tumor | <0.8 mm without ulceration | <0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration | >1.0-2.0 mm without ulceration | >1.0-2.0 mm with ulceration | >2.0-4.0 mm without ulceration | >2.0-4.0 mm with ulceration | >4.0 mm without ulceration | >4.0 mm with ulceration |



| N Category | Number of tumor-involved regional lymph nodes | Presence of in-transit, satellite and/or microsatellite metastases |
|---|---|---|
| N0 | No regional metastases detected | No |
| N1a | 1 clinically occult (i.e., detected by SLN biopsy) | No |
| N1b | 1 clinically detected | No |
| N1c | No regional lymph node disease | Yes |
| N2a | 2 or 3 clinically occult (i.e., detected by SLN biopsy) | No |
| N2b | 2 or 3, at least 1 of which was clinically detected | No |
| N2c | 1 clinically occult or clinically detected | Yes |
| N3a | ≥4 clinically occult (i.e., detected by SLN biopsy) | No |
| N3b | ≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes | No |
| N3c | ≥2 clinically occult or clinically detected and/or presence of any number of matted nodes | Yes |




Melanoma-Specific Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.0
1
2
3
4
5
6
7
8
9
10
Years Since Diagnosis
N 5-YR 10-YR
IA 5225 99% 98%
IB 5749 97% 94%
IIA 2338 94% 88%
IIB 1688 87% 82%
IIC 691 82% 75%


Melanoma-Specific Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
2
4
6
8
10
Years Since Diagnosis
N 5-YR 10-YR
IIIA 1006 93% 88%
IIIB 1170 83% 77%
IIIC 2201 69% 60%
IIID 205 32% 24%

# M Staging

- What is needed for melanoma M staging?
  - Anatomy involved
  - Don’t forget LDH

| M Category | M Criteria | |
|---|---|---|
| | Anatomic site | LDH level |
| M0 | No evidence of distant metastasis | Not applicable |
| M1 | Evidence of distant metastasis | See below |
| M1a | Distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node | Not recorded or unspecified |
| M1a(0) | | Not elevated |
| M1a(1) | | Elevated |
| M1b | Distant metastasis to lung with or without M1a sites of disease | Not recorded or unspecified |
| M1b(0) | | Not elevated |
| M1b(1) | | Elevated |
| M1c | Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease | Not recorded or unspecified |
| M1c(0) | | Not elevated |
| M1c(1) | | Elevated |
| M1d | Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease | Not recorded or unspecified |
| M1d(0) | | Normal |
| M1d(1) | | Elevated |

Suffixes for M category: (0) LDH not elevated, (1) LDH elevated.
No suffix is used if LDH is not recorded or is unspecified.

# Pathological subtypes

- Superficial spreading (70%), worst prognosis
- Lentigo maligna (insitu – freckle), lentigo maligna melanoma (invasive)
  - 10% LN positive, 5y OS 85% WLE alone
- Acral lentiginous
  - Increased in dark skinned, palms, soles
- Nodular (no radial growth)
- Desmoplastic
  - Older, more PNI, increased LR, decreased LN
- Mucosal melanoma (1%)

# Presentation

- 5% with DM at diagnosis
  - 33% of these with unknown primary
- 85% with localized disease
- 10% present with regional disease

# Workup

- Stage I-II
  - Imaging only to evaluate specific symptoms
- Stage III
  - SLN+ consider baseline imaging
  - cN+ or intransit, local and distant imaging
- SLNB if:
  - >0.75mm
  - Consider if ulceration, LVSI, and/or mitotic rate >=1mm2
- Clinical LN exam has 20% discordance

# NCCN Margins

**PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA**

| Tumor Thickness | Recommended Clinical Margins[b] |
|---|---|
| In situ[a] | 0.5–1.0 cm |
| ≤1.0 mm | 1.0 cm (category 1) |
| >1.0–2 mm | 1–2 cm (category 1) |
| >2.0–4 mm | 2.0 cm (category 1) |
| >4 mm | 2.0 cm (category 1) |

- Margins may be modified to accommodate individual anatomic or functional considerations.
- Consider histologic margin assessment prior to reconstruction and closure.

# Treatment of locally advanced melanoma

- Care pathways complex, evolving as evidence for systemic therapy advances
- High-dose interferon-α x1 year after resection for high risk melanoma
  - Stages IIB, IIC, III
  - Many trials – ECOG 1684/1690/1694
- Adjuvant ipilumumab in stage III disease (EORTC 18071)

# Post-hoc meta-analysis of EORTC 18952 18991, Eggermont et al, 2012




Stage IIb/III-N1: HR 0·58 (99% CI 0·40–0 · 86), p=0·0003.
Stage III-N2: HR 0·89 (99% CI 0·62 to –1· 28), p=0·41.

# EORTC 18071 – Long term followup, Eggermont et al, 2019



# Another win for immunotherapy – SWOG S1801

# Neoadjuvant vs Adjuvant IO



# Adjuvant RT

- **TROG 02.01** (Burmeister Lancet ‘12, Henderson ‘15)
  - Palpable LND +- ISRT 48 Gy / 20 fr (margin+ 51 Gy/21)
  - SLNB not allowed
  - Nonmetastatic palpable LN at dx or at LN relapse
  - 1 parotid, 2 neck, 2 axilla, 3 groin, >=3cm neck, >=4cm axillary/inguinal
    - **“1,22,33,4”**
  - <5% of patients got adjuvant interferon

# TROG 02.01




***Figure 2:*** **Cumulative incidence curves of lymph-node field relapse as a site of first relapse (competing risks: other relapse and death)**




***Figure 3:*** **Overall survival of eligible patients**

# Adjuvant RT indications

- Burmeister criteria
- Usually in nodal recurrences, given no survival differences
- No randomized controlled trial of adjuvant immunotherapy vs RT
- Also consider ECE, >4mm esp if ulcerated or with satellitosis, and SLNB+ without completion dissection

# Hypofractionation – 30 Gy / 5 2-3x/week

- Several phase II studies, retrospective
  - MDACC – Ang IJROBP ‘94, Ballo Cancer ’06
- UF 60Gy /30 vs 30 Gy/ 5
  - Chang IJROBP ‘09

- Bottom line
  - Probably equally as efficacious as moderate hypo or standard frac
  - Late toxicity a bit worse, cosmesis worse

# Definitive RT

- a/b ratio ~ 0.4-2.5
- Retrospective data showed increasing efficacy with fraction size
  - Lead to RTOG 8305 – definitive palliation of 32 Gy/4 fr vs 50 Gy / 20
    - No difference in LR< 32 Gy toxic with G4 toxicity
    - CR ~ 25%
- 50-55Gy/20 daily
- 42 Gy – 54 Gy / 6 biweekly

# NCCN - Metastatic Disease



# Metastatic disease

- Ipilimumab – CTLA4 antibody
  - Improves OS
- Vemurafenib, Dabrafenib (BRAF inhibitors, V600 mutation)
- IL-2
- Imatinib (C-kit)


enhanced immune function
plus IT
DCs
Tumour
I WANT TO BELIEVE

# NB: Abscopal effect

- First described clinical complete response for pathologically involved neck lymph nodes second to recurrent erysipelas in 1891, reported in 1914 by William B Coley
- Radiation therapy apt to induce abscopal in melanoma, albeit rare
  - Perhaps more likely in patients treated with immunotx
  - Perhaps more likely with ablative or high dose/fraction treatments



# Non-Melanoma Skin Cancers

SCC and BCC

# Epidemiology – Geographic Variation






**Figure 4.** Lifetime risk for developing basal cell carcinoma in males (BCC[M]) and females (BCC[F]) and Squamous Cell Carcinoma in males (SCC[M]) and females (SCC[F]) in Manitoba, British Columbia, Alberta, New Brunswick, and the US.

# SCC and BCC Risk Factors

- Older age
- Higher UV exposure (UVB > UVA)
- Skin type
- Prior RT exposure
- Chronic inflammation (SCC>BCC)
- Chemical exposure
- Immune deficiency
  - Transplant
  - SLL/CLL

# BCC, SCC Genetics

# Gorlin syndrome

- (basal cell nevus syndrome, PTCHmt)
- Autosomal dominant
- Multiple BCCs, RMS, medulloblastoma, fibrosarcomas, palmar/plantar pits, frontal bossing, bifid ribs, bone cysts
- Classically, avoid irradiating these patients





# Bazex-Dupre-Christol syndrome

- X-linked, dominant
- Multiple BCC and pitting ‘ice pick’ scars on the skin



# Xeroderma pigmentosum

- Xeroderma pigmentosum:
  - X-linked
  - Increased sensitivity to UV radiation
  - 1000 increased risk of skin cancer (~57% lifetime risk)
  - Faulty NER repair



- Albinisim
  - 35% lifetime risk of skin cancer
- Muir-Torre syndrome
  - Autosomal dominant
  - Sebaceous skin tumours, eyelid, GI/GU malignancies
  - Associated with MSH-1 and MLH-1 (DNA MMR genes)



Muir-Torre syndrome

# BCC Genetics

- >90% associated with abnormal hedgehog pathway signaling
- Vismodegib acts on the Sonic Hedgehog Pathway (SHH)

# BCC Pathologies

- Nodular (60%) – papule
- Superficial (30%) – scaly macule
- Morpheaform (5-10%)
  - More likely to have infiltrating growth
- Infiltrative, Basoquamous (rare)
  - More aggressive, behave more similar to SCC

# BCC Natural History

- Locally aggressive
- 0.1% PNI
  - CN V, VII most likely
- <1% metastasize

# SCC Pathologies

- SCC in Situ – Bowen’s disease
- Superficial
- Spindle cell

# SCC Natural history

- Actinic Keratosis is premalignant lesion
  - 6-10% of invasive SCC in 10 years if multiple AK's
- PNI ~10%
- ~5% metastases
  - P16 positive in ~1/3 but not prognostic

# SCC Lymph Node Risk

- G1
  - LN~1%
- G3, >3cm, DOI >4mm, lips, and temporal lesions
  - LN~15%
- Originating in burn scar or osteomyelitis
  - LN~30%

# SCC Distant Risk

- Brantsch Lan Onc ‘08
  - Prospective series
  - 615 patients, MFU ~4y
- Increased tumor thickness >6mm
- Immunosuppresion
- Location on the ear (up to 10% DM)
- Increased tumor diameter
  - <2cm, DM 1.9%
  - >2cm DM 7.5%
  - >5cm, DM 20%



**TABLE 17.3: AJCC 8th ed. (2017) Staging System for Cutaneous Squamous Cell Carcinoma**

| T/M \ N | | cN0 | cN1 | cN2a | cN2b | cN2c | cN3a | cN3b |
|---|---|---|---|---|---|---|---|---|
| **T1** | • <2 cm | **I** | **III** | **IVA** | | | | |
| **T2** | • 2.1–4 cm | **II** | | | | | | |
| **T3** | • >4 cm<br>• 1 high risk feature[1] | | | | | | | |
| **T4a** | • Gross cortical bone | **IVA** | | | | | | |
| **T4b** | • Invasion into skull base | **IVB** | | | | | | |
| **M1** | • Distant metastasis | **IVC** | | | | | | |

*Notes:* 1 high risk feature[1] = Minor bone erosion, PNI (nerve measuring ≥0.1 mm), or deep invasion (beyond subcutaneous fat or >6 mm depth). Nodal category definition is similar to other non-HPV-associated head and neck cancers; see Table 10.4 for clinical and pathologic nodal categories.

**TABLE 17.4: Brigham and Women's Hospital Staging System for Cutaneous Squamous Cell Carcinoma**

| | | 10-yr LR | | High-Risk Factors |
|---|---|---|---|---|
| **T1** | 0 High-risk factors | 0.6% | | Tumor ≥2 cm |
| **T2a** | 1 High-risk factor | 5% | | Poor differentiation |
| **T2b** | 2–3 High-risk factors | 21% | | PNI ≥0.1 mm |
| **T3** | ≥4 High-risk factors | 67% | | Tumor beyond fat (bone invasion automatically T3) |

# Prognosis - Karia, JCO 2014



# Surgery or RT?




**Figure 1** Kaplan–Meier plot of recurrent or persistent BCC in patients treated with surgery or radiotherapy. Bars indicate 95% confidence intervals. - - -, Surgery ($n$ = 174, one event); —, radiotherapy ($n$ = 173, 11 events)

*British Journal of Cancer* (1997) **76**(1), 100–106


## Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study

**M-F Avril[1], A Auperin[2], A Margulis[3], A Gerbaulet[4], P Duvillard[5], E Benhamou[2], J-C Guillaume[6], R Chalon[1], J-Y Petit[7], H Sancho-Garnier[8], M Prade[5], J Bouzy[2] and D Chassagne[4]**

[1]Service de dermatologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France; [2]Départements de [2]biostatistique et d'épidémiologie, [3]chirurgie générale, [4]radiothérapie and [5]anatomopathologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France; [6]Service de dermatologie, Centre Hospitalier Louis Pasteur, 68021 Colmar Cedex, France; [7]Service de chirurgie plastique, Institut Européen d'Oncologie, Via Ripamonti 435, 20141 Milan, Italie; [8]Epidaure, Parc Euromédecine, 34298 Montpellier Cedex 5, France

Among the 173 patients in the radiotherapy group, 95 were treated with interstitial brachytherapy, 57 with contactherapy, 20 with conventional radiotherapy and one with surgery. Contactherapy was applied to smaller BCCs (8.4 mm, s.d. = 3.2), brachytherapy used for intermediate sized BCCs (12.9 mm, s.d. = 5.8) and conventional radiotherapy for the largest BCCs (15.5 mm, s.d. = 5.8).

For brachytherapy, the silk suture technique was used in 87 cases. The range of the doses delivered was 57–76 Gy. Forty-five patients received 65 Gy and 27 received 70 Gy. Most of the time, two or three radioactive lines were used (70 and 23 patients respectively). Local anaesthesia was performed in 80 patients. The mean duration of hospitalization was 6.9 days (s.d. = 1.8).

The range of the dose delivered by contactherapy was 34–40 Gy, with two-thirds of the patients receiving 36 Gy.

The doses delivered by conventional radiotherapy were 60 Gy in 18 cases, 65 Gy in one case and 33 Gy in another case. The duration of treatment varied 5–7 weeks.

# Comparing Modalities

| Technique | Low risk LC | High Risk LC |
|---|---|---|
| Surgical excision with post operative margin assessment | 90-95% | 83-88% |
| Mohs | 99% | 90-94% |
| RT | 90-96% | 80-88% |

More details in recent metaanalysis - Lee et al, Cancer 2020

# ASTRO Guidelines – Likhacheva, PRO 2019

Key questions and recommendations:

- Indications for definitive RT
- Indications for postoperative RT
- Indications for treating regional nodes and regional disease management
- Radiation techniques and dose-fractionation schedules for primary site management
- Use of chemotherapy, biologic, and immunotherapy agents before, during, or after RT

**Table 4.** Recommendations for definitive RT

| KQ1 Recommendations | Strength of Recommendation | Quality of Evidence (Refs) |
|---|---|---|
| 1. In patients with BCC and cSCC who cannot undergo or decline surgical resection, definitive RT is recommended as a curative treatment modality. | Strong | Moderate [3-8] |
| 2. In patients with BCC and cSCC in anatomical locations where surgery can compromise function or cosmesis, definitive RT is conditionally recommended as a curative treatment modality. | Conditional | Moderate [9-11] |
| 3. Definitive RT for BCC and cSCC is conditionally **not** recommended in patients with genetic diseases predisposing to heightened radiosensitivity. | Conditional | Expert Opinion |

*Abbreviations*: BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; KQ = key question; RT = radiation therapy.

# Definitive RT

- Central lesions >5mm
  - Nasal ala
  - Eyelids
  - Tip of nose
  - Lip commissure
- Lesions >2cm
  - Forehead
  - Scalp

- (relative) contraindications
  - Poor blood supply or high trauma
    - Dorsum of hand
    - Belt line
    - Shin
  - Previous RT to area
  - Exposed cartilage/bone
  - Gorlin syndrome
  - XP

**Table 5.** Recommendations for PORT

| KQ2 Recommendations | Strength of Recommendation | Quality of Evidence (Refs) |
|---|---|---|
| **Both BCC and cSCC** | | |
| 1. PORT is recommended for gross perineural spread that is clinically or radiologically apparent. | Strong | Moderate [29,33-36] |
| **cSCC** | | |
| 2. PORT is recommended for patients with cSCC having close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome). | Strong | Low [37] |
| 3. PORT is recommended for patients with cSCC in the setting of recurrence after a prior margin-negative resection. | Strong | Moderate [38-43] |
| 4. In patients with cSCC, PORT is recommended for T3 and T4 tumors.* | Strong | Moderate [44-46] |
| 5. In patients with cSCC, PORT is recommended for desmoplastic† or infiltrative tumors in the setting of chronic immunosuppression. | Strong | Moderate [44,46] |
| **BCC** | | |
| 6. PORT is conditionally recommended in patients with BCC with close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome). | Conditional | Low [8,24] |
| 7. PORT is conditionally recommended in patients with BCC in the setting of recurrence after a prior margin-negative resection. | Conditional | Low [8,24,47,48] |
| 8. PORT is conditionally recommended in patients with BCC with locally advanced or neglected tumors involving bone or infiltrating into muscle. | Conditional | Low [8,24,45] |

*Abbreviations:* BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; KQ = key question; PORT = postoperative radiation therapy; RT = radiation therapy.

* American Joint Committee on Cancer staging table, eighth edition.[2]

† The presence of desmoplasia on light microscopy is defined as fine branches of tumor cells at the periphery and a surrounding stromal reaction. All cSCC in which at least one-third of the representative tumor specimen meet these criteria is classified as desmoplastic cSCC. One study reported findings that perineural or perivascular invasion were always associated with desmoplasia.[46]

# Indications for Adjuvant RT

- Primary
  - Margin+
  - Extensive PNI
    - >0.1=mm nerve or widespread/multiple involvement
  - pT3-4
  - SCC mets to parotid
- Nodes
  - ECE
    - Can consider surveillance in pN2a so longa s ECE not present
  - ENI if recurrent after surgery
  - G3, >3cm, and/or large infiltrative-ulcerative SqCC
  - Parotid coverage (if intact) for post op face
  - 2cm margin for post op scalp lesion (Wojckicka RTO ‘09)

# Adjuvant RT for PNI?

**INTRODUCTION**

Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer, accounting for 20% to 50% of all skin cancers.[1] The incidence of cSCC is continuing to rise with increases of 50% to 200% reported over the past 3 decades.[2-4] Although 96% of cSCCs can be treated successfully with wide local excision or Mohs micrographic surgery, there is a subset of cSCCs that are associated with higher rates of local recurrence, metastasis, and disease-specific death.[5,6] High-risk features for this subset of cSCCs include tumor diameter of >2 cm, perineural invasion (PNI) of nerves >0.1 mm in caliber, tumor depth beyond subcutaneous fat, poorly differentiated histology, the previously irradiated or recurrent tumor, location in the ear or the lip, tumor arising within scar, and immunosuppression.[7-9]

The role of adjuvant radiotherapy for these high-risk cSCCs remains unclear. Current National Comprehensive Cancer Network (NCCN)

**CAPSULE SUMMARY**

- The indications for adjuvant radiotherapy after margin-negative resection for high-risk cutaneous squamous cell carcinomas are unclear.
- This meta-analysis found that adjuvant radiotherapy did not significantly change local recurrence, nodal metastases, regional metastases, and disease-specific death. Randomized controlled trials are necessary to define the benefit of adjuvant radiotherapy in this setting.

**Evidence acquisition**

The population, intervention, control, outcome, and study design method was used to define literature inclusion criteria (Supplementary Table I, available via Mendeley at https://data.mendeley.com/datasets/ytmw6yncpn/1).[12-14] The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines[15] and the Meta-analysis of Observational Studies in Epidemiology reporting guidelines[16] were used (Supplementary Fig 1, available via Mendeley at https://data.mendeley.com/datasets/ytmw6yncpn/1). A comprehensive and systematic search of PubMed/MEDLINE, Embase, and the Cochrane Database of Systematic Reviews from 2006 to 2020 was performed by 2 experienced librarians with input from the study's principal investigator (CL) and the lead author (YK). Literature published before 2006

**Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis**

Yesul Kim, MD,[a] Eric J. Lehrer, MD, MS,[b] Paul J. Wirth, MD,[a] Eiman A. Khesroh, MBBS, MPH,[c] Jerry D. Brewer, MD, MS,[d] Elizabeth M. Billingsley, MD,[a] Nicholas G. Zaorsky, MD, MS,[e] and Charlene Lam, MD, MPH[a]

*Hershey, Pennsylvania; New York, New York; Rochester, Minnesota; and Fairport Harbor, Ohio*

**Table 7.** Recommendations for radiation techniques and dose-fractionation schedules for primary site management

| KQ4 Recommendations | Strength of Recommendation | Quality of Evidence (Refs) |
|---|---|---|
| 1. In patients with BCC and cSCC receiving RT in the definitive setting, the following dose-fractionation schemes* are recommended:<br>○ Conventional (180–200 cGy/fx): $BED_{10}$ 70–93.5<br>○ Hypofractionation (210–500 cGy/fx): $BED_{10}$ 56–88<br><br>**Implementation Remark**: Conventional fractionation is delivered 5 days per week; hypofractionation is delivered daily or 2-4 times per week. | Strong | Low<br>10,79,80,82,88-94 |
| 2. In patients with BCC and cSCC receiving RT in the postoperative setting, the following dose-fractionation schemes* are recommended:<br>○ Conventional (180–200 cGy/fx): $BED_{10}$ 59.5–79.2<br>○ Hypofractionation (210-500 cGy/fx): $BED_{10}$ 56–70.2<br><br>**Implementation Remark:** Conventional fractionation is delivered 5 days per week; hypofractionation is delivered daily or 2-4 times per week. | Strong | Low<br>5,48,90,93,95-100 |

*Abbreviations:* BCC = basal cell carcinoma; $BED_{10}$ = biologically effective dose assuming an $\alpha/\beta = 10$; cSCC = cutaneous squamous cell carcinoma; fx = fraction; KQ = key question; RT = radiation therapy.

* See Table 8 with specific fractionation schemes.

**Figure 2.** Dose fractionation summary

| Dose (cGy) \ # of Fractions | 8 | 9 | 10 | 11 | 14 | 15 | 16 | 17 | 18 | 20 | 28 | 30 | 33 | 35 | 36 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 | | | | | | | | | | | 5040 | | 5940 | | 6480 |
| 200 | | | | | | | | | | | | 6000 | 6600 | 7000 | |
| 250 | | | | | | | | | | 5000 | | | | | |
| 275 | | | | | | | | | | 5500 | | | | | |
| 300 | | | | | 4200 | 4500 | 4800 | 5100 | 5400 | | | | | | |
| 340 | | | | | | | | | 6120 | | | | | | |
| 400 | | | | 4400 | | | | | | | | | | | |
| 440 | | | 4400 | | | | | | | | | | | | |
| 450 | | 4050 | 4500 | | | | | | | | | | | | |
| 500 | 4000 | | | | | | | | | | | | | | |

# PRINCIPLES OF RADIATION THERAPY

## General Principles

- Protracted fractionation is associated with improved cosmetic results and should be utilized for poorly vascularized or cartilaginous areas.
- For extensive perineural invasion, clinically evident perineural involvement, or involvement of named nerves (particularly in the head and neck region), consider including the course of the local nerves proximally.
- RT is contraindicated for genetic conditions predisposing to skin cancer (eg, basal cell nevus syndrome) and relatively contraindicated for patients with connective tissue diseases (eg, scleroderma).
- Given higher complication rates, re-irradiation should not be routinely utilized for recurrent disease within a prior radiation field.
- Isotope-based brachytherapy can be an effective treatment for certain sites of disease, particularly on the head and neck.
- There are insufficient long-term efficacy and safety data to support the routine use of electronic surface brachytherapy.

## General Treatment Information

| Primary Tumor | Examples of Dose Fractionation and Treatment Duration |
|---|---|
| **Definitive RT** | |
| Tumor diameter <2 cm | 60–64 Gy over 6 to 7 weeks<br>50–55 Gy over 3 to 4 weeks<br>40 Gy over 2 weeks<br>30 Gy in 5 fractions over 2 to 3 weeks |
| Tumor diameter ≥2 cm, T3/T4, or those with invasion of bone or deep tissue | 60–70 Gy over 6 to 7 weeks<br>45–55 Gy over 3 to 4 weeks |
| **Postoperative Adjuvant RT** | 60–64 Gy over 6 to 7 weeks<br>50 Gy over 4 weeks |
| **Regional Disease** | |
| • Lymph node regions, after lymph node dissection | |
| ▸ Negative margins, no ECE | 50–60 Gy over 5 to 6 weeks |
| ▸ Positive margins or ECE | 60–66 Gy over 6 to 7 weeks |
| • Lymph node regions, without lymph node dissection | |
| ▸ Clinically negative, at risk | 50 Gy over 5 weeks |
| ▸ Clinically positive | 60–70 Gy over 6 to 7 weeks |
| • Clinically at-risk nerves | 50–60 Gy over 5 to 6 weeks |

# Dosing – UK Survey, McPartlin, BJR 2014

Table 1. Popularity of commonly suggested dose fractionations

| Dose fractionation | Number of times suggested |
|---|---|
| 18 Gy/1# | 41 |
| 20 Gy/1# | 18 |
| 32 Gy/5# | 27 |
| 35 Gy/5# | 237 |
| 40.5 Gy/9# | 22 |
| 40 Gy/10# | 29 |
| 45 Gy/10# | 170 |
| 45 Gy/9# | 51 |
| 45 Gy/15# | 15 |
| 50 Gy/15# | 56 |
| 50 Gy/20# | 57 |
| 55 Gy/20# | 134 |
| 60 Gy/30# | 26 |
| 66 Gy/33# | 11 |
| 27 Gy/3# over 2 weeks | 20 |
| 28 Gy/2# over 6 weeks | 11 |
| 38 Gy/6# over 6 weeks | 11 |
| 45 Gy/9# over 3 weeks | 24 |

Figure 1. Fractionation regimes employed for a given scenario in different patient groups. BCC, basal cell carcinomas; SCC, squamous cell carcinomas.



Figure 2. Radiation modality employed for given scenario in different patient groups. BCC, basal cell carcinomas; kv, kilovoltage; SCC, squamous cell carcinomas.



# How to choose?

- Can only treat with what you have available
- If you have choice, is a balance between
  - Practicality
  - Resources
  - Toxicity/Anatomy
- Need to know both orthovoltage and electrons well for your exams

# Post operative head and neck guidelines – IJROBP 2020

Clinical Investigation

## Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Sandro V. Porceddu, MBBS, FRANZCR, MD,[*,†] Christopher Daniels, MBBS, FRANZCR,[*] Sue S. Yom, MD, PhD,[‡] Howard Liu, MBBS, FRANZCR,[*,†] John Waldron, MD, FRCPC, MSc,[§,‖] Vincent Gregoire, MD, PhD,[¶] Alisha Moore, BMedRadSci(RT),[#,**] Michael Veness, MBBS, MD, MMed (Clin Epi), FRANZCR,[††,‡‡] Min Yao, MD, PhD,[§§] Jorgen Johansen, MD, PhD,[‖‖] Hisham Mehanna, PhD, BMedSc, MB ChB, FRCS, FRCS (ORL-HNS),[¶¶] Danny Rischin, MBBS, FRACP, MD,[##,***] and Quynh-Thu Le, MD[†††]

*Princess Alexandra Hospital, Brisbane, Australia; [†]University of Queensland, Queensland, Australia; [‡]University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California; [§]Princess Margaret Cancer Centre, Toronto, Canada; [‖]University of Toronto, Toronto, Canada; [¶]Centre Leon Berard, Lyon, France; [#]Trans Tasman Radiation Oncology Group, Newcastle, Australia; **University of Newcastle, Newcastle, Australia; [††]Westmead Hospital, Westmead, Australia; [‡‡]University of Sydney, Sydney, Australia; [§§]Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio; [‖‖]Odense University Hospital, Denmark; [¶¶]University of Birmingham, United Kingdom; [##]Peter MacCallum Cancer Center,

# Post Operative Volumes

**Table 1** Summary of target volume definitions

| Target volume | Structure | Definition |
|---|---|---|
| Site of primary tumor before excision* | HRTVp | The volume that represents the preoperative primary site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings |
| Site of involved lymph nodes before excision* | HRTVn | The volume that represents the preoperative regional nodal site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings |
| Subsite of the HRTVp likely to carry a higher burden of microscopic disease (ie, positive or margin clearance <2 mm) and warranting a boost dose | HRTVp_Boost | The subvolume that represents the preoperative primary site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings and considered at particularly high risk |
| Subsite of the HRTVn disease likely to carry a higher burden of microscopic disease (ie, positive margin or extranodal extension) | HRTVn_Boost | The volume that represents the preoperative regional nodal site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings and considered at particularly high risk |
| Primary site high-risk clinical target volume | CTVp_HR | Minimum volume includes HRTVp + 5 mm isotropic expansion and modified to anatomic barriers. May also include the entire operative bed, reconstruction flap, or graft site. Resected LNPNS |
| Nodal site high-risk clinical target volume | CTVn_HR | Minimum volume includes HRTVn + 5 mm isotropic expansion and modified to anatomic barriers. May also include the entire involved neck node level/basin or neck dissection/parotidectomy bed |
| Primary site lesser risk clinical target volume | CTVp_LR | The primary site operative bed that does not meet the criteria for CTVp_HR and modified to anatomic barriers. May also include the broader operative bed, reconstruction flap, or graft site. For LNPNS it also includes the undissected zone proximal to the involved zone |
| Nodal site lesser risk clinical target volume | CTVn_LR | The nodal dissection operative bed that does not meet the criteria for CTVn_HR, modified to anatomic barriers, and next echelon of surgically undisrupted clinically uninvolved nodes (elective) |
| Primary tumor boost site (optional) | CTVp_HR_Boost | Minimum volume includes HRTVp_Boost + 5 mm expansion and modified to anatomic barriers |
| Nodal site boost site (optional) | CTVn_HR_Boost | Minimum volume includes HRTVn_Boost + 5 mm expansion and modified to anatomic barriers |

*Abbreviations*: CT = computed tomography; CTV = clinical target volume; GTV = gross tumor volume; HR = high risk; HRTV = high-risk tumor volume; LNPNS = large nerve perineural spread; LR = low risk; n = nodal; p = primary.

* Where there is substantial overlap of the HRTVp and HRTVn, a single HRTV termed HRTVp/n may be used (eg, an extensive primary lesion over the preauricular area with underlying intraparotid nodal metastases).

# Post Operative Doses

**Table 2** Summary of recommended minimum prescribed doses*

| Target volume | IMRT technique | Non-IMRT technique |
|---|---|---|
| PTVp_HR and/or PTVn_HR | 60.0 Gy in 30 fractions | 60.0 Gy in 30 fractions |
| PTVp_LR and/or PTVn_LR | 56.0 Gy in 30 fractions<br>Optional: 54.0 Gy in 30 fractions for surgically undisrupted LR region | 54.0 Gy in 27 fractions<br>Optional: 50.0 Gy in 25 fractions for surgically undisrupted LR region |
| PTVp_boost and/or PTVn_boost (optional) | 66.0 Gy in 33 fractions or 63.0 Gy in 30 fractions | 66.0 Gy in 33 fractions |

*Abbreviations*: HR = high risk; IMRT = intensity modulated radiation therapy; LR = lesser risk; n = nodal involvement; p = primary site; PTV = planning target volume.

* Fractionation schedules are described as once daily at 5 fractions per week.

Variance exists, and ok to use SIB with slight hypofraction at RO's discretion (ie 63-66Gy/ 30-33 fr) – see last line

# H Zone



BMJ

BMJ 2012;345:e5342 doi: 10.1136/bmj.e5342 (Published 21 August 2012)



CLINICAL REVIEW

Facial basal cell carcinoma

# TROG 05.01 – RT +- carboplatin

VOLUME 36 · NUMBER 13 · MAY 1, 2018

JOURNAL OF CLINICAL ONCOLOGY | ORIGINAL REPORT

## Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial

*Sandro Virgilio Porceddu, Mathias Bressel, Michael Geoffrey Poulsen, Adam Stoneley, Michael John Veness, Lizbeth Moira Kenny, Chris Wratten, June Corry, Stephen Cooper, Gerald Blaise Fogarty, Marnie Collins, Michael Kevin Collins, Andrew Martin John Macann, Christopher Gerard Milross, Michael Gordon Penniment, Howard Yu-hao Liu, Madeleine Trudy King, Benedict James Panizza, and Danny Rischin*




**Fig 2.** Kaplan-Meier estimates of (A) freedom from locoregional relapse, (B) disease-free survival, and (C) overall survival by treatment arm. CRT, chemoradiotherapy; RT, radiotherapy.

| Table 1: Systemic Therapy Options for Use with RT | | |
|---|---|---|
| **Preferred Regimens** | **Other Recommended Regimens** | **Useful in Certain Circumstances** |
| • Cisplatin[2]<br>• Clinical trial[3,4] | • None | • EGFR inhibitors (eg, cetuximab)[2]<br>• Cisplatin + 5-FU[2]<br>• Carboplatin ± paclitaxel[2,5,6] |

# NCCN - Concurrent options


IF CETUXIMAB WAS A PERSON...
I'm not totally useless.
I can be used as a bad example.
imgflip.com


BILLY!
WHAT HAVE YOU DONE?!
CETUXIMAB IS THE BEST DRUG EVER MADE
LET ME HELP YOU SON
imgflip.com

# Treatment Planning Considerations

# CTV Margins

- BCC
  - Well defined, <2cm
    - 0.5-**1.0cm**
  - >2cm
    - 1-**1.5cm**
  - Use the larger CTV for infiltrative, poorly defined histologies
  - 0.5cm depth, 0.25 if mobile, thin skin
- SCC
  - Well defined, <2cm
    - 1.1cm
  - High risk features, >2cm
    - 1-**1.5cm**
  - Min 0.5cm depth

Need to tailor to patient, anatomy, technique, and fractionation!

IJROBP Khan et al 2011

Rad & Onc Khan et al 2012

# What about PTV?

- PTV/penumbra depends on technique
- IMRT
  - PTV +3-5mm depending on setup, IGRT
- ICRU model breaks down somewhat for clinical setups
- Electrons
  - +5-10mm for penumbra
- Orthovoltage
  - PTV/Penumbra 2-3mm, though often collimated to ~CTV

| Orthovoltage | Electrons |
| --- | --- |
| **Advantages:**<br>• Better beam flatness<br>• Sharper penumbra<br>• Maximum dose at skin<br>• Smaller margin<br>• Smaller fields<br>• No bolus | **Advantages:**<br>• No F – factor<br>• Greater depth dose with appropriate energy to treat large or thick lesions<br>• Can have sharper fall off/less exit dose than orthovoltage if prescribed appropriately |
| **Disadvantages:**<br>• High bone absorption (F-factor/photo electric effect)<br>• Limited penetration/not ideal for thick or deep lesions | **Disadvantages:**<br>• Dosimetry may be more complex<br>• Skin sparing effect, need bolus for surface dose at lower energies<br>• Larger field size<br>• Electron back scatter<br>• RBE effects |

# Stand-off correction factor




**Fig 16.3** (a) Positive stand-off of 0.5 cm between lesion and applicator. (b) Negative stand-off of 0.5 cm.

# Orthovoltage PDD



# Case 1 – BCC of Anterior Pinna



- 1cm margin around full thickness of pinna
- 5cm circle applicator
- 150 kV photons
- HVL 6mm Al
- Shield behind ear
- Bolus*
- 50 Gy / 20

# Case 2 – BCC of Nasal Ala



- 0.7cm margin around full thickness of pinna
- 3cmcm circle applicator
- 150 kV photons
- HVL 6mm Al
- 50 Gy / 20
- Shield in left nostril to protect nasal septum
- Consider shield in upper gum

# Case 3 - SCC of Preauricular skin



- Electrons modality of choice
  - Spares brain
- Tissue equivalent plug into ear canal to reduce funneling of dose into eardrum and middle ear
- 12 MeV + 0.5cm bolus to 90%
- 66 Gy in 30 fractions
  - RBE is ~0.9

# Dose Distributions




Radiation Oncology Physics: A Handbook for Teachers and Students – 8.1.1

# Electron PDD



# Field size effect on electron PDD




Incident electron
Absorber
(b)
Electron absorbed






**Figure 2.** (a) Schematic view of modern day treatment head configuration. Note the 270° achromatic bending magnet that redirects the electron beam towards the patient. (b) Schematic view of treatment head configured for electron beam delivery. Note the scattering foil (actually dual-scattering foils separated 5–10 cm) to broaden the beam, secondary (x-ray) collimator and electron applicator to collimate the beam and ion chamber (actually dual, segmented ionization chamber) used to monitor the beam (from Karzmark and Morton (1989)).

# Electron Cutouts - Standard

- Available in a variety of sizes
- Applicators range from 10 cm x 10 cm up to 25 cm x 25 cm in size

# Electron Cutouts - Custom



# Custom Cutouts

- Old technology
  - Minimum requirements – 200MHz processor
  - Recommended requirements – Pentium 500MHz
  - On its last legs
- Moving from Cerrobend to Copper cutouts – '***soon***'
  - Lead safety process improvements – important!





# Skin Brachytherapy

- Common approaches
  - Surface moulds
  - Electronic brachytherapy approaches
    - Valencia and Leipzig applicators
  - Freiburg Flap applicator
- Electronic brachytherapy becoming more common in USA, especially in dermatology practices as energies required do not need MV or active source radiation license

# Freiburg flap applicator




J. Park et al, JACMP 2014

# Surface Moulds

Clinical Investigations

Original paper

## High-dose-rate skin brachytherapy with interstitial, surface, or a combination of interstitial and surface mold technique

Serhii Brovchuk, PhD[1], Sang-June Park, PhD[2], Zoia Shepil, MD[1], Serhii Romanenko, MD[1], Oleg Vaskevych, MD[1]

[1]Radiotherapy Department, Kyiv Regional Oncology Dispensary, Kyiv, Ukraine, [2]Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA

Fig. 1




A 62-year-old patient with basal cell carcinoma (BCC), superficial treatment. **A, B**) On first day of treatment

# Valencia Applicator



- Has a flattening filter
  - Slower dose rate
  - Flatter edges
- 3cm applicator for a 2.5cm lesion

# Leipzig applicator



- No flattening filter, faster
- Less uniform isodose, larger ‘penumbra’
- 3cm diameter for 2cm lesion

# Interstitial skin brachytherapy

- Excellent for conformal treatment for thicker lesions, face, more suitable for hypofractionated/accelerated treatment
- Excellent OAR sparing, especially near orbit
- Depending on bulk, may need surface mould, more than a single plane of applicators if >5mm depth

# Interstitial Skin Brachytherapy




**Fig. 5.** A 63-year-old patient with BCC, interstitial treatment of two localizations. **A**, **B**) First day of treatment, **C**, **D**) six's day of treatment, and **E**, **F**) three months after BT

# Overlap between Surface brachytherapy and Orthovoltage cases




**Fig. 2.** An example of an 82-year-old female patient, who presented with a lesion of the medial inferior eyelid (**A**). Flap
plicator was placed, and thermoplastic mask was created to secure its position (**B**). Simulation CT was obtained (**C**). 40 G
8 twice weekly fractions was delivered using HDR-brachytherapy. During the final week of treatment, she developed gra
onjunctivitis, which was treated with a two-day course of antibiotic/steroid eye suspension. On initial follow-up one-mo
st-treatment, her conjunctivitis had resolved, and the lesion had diminished in size. By follow-up at seven months, her le
completely resolved, with minimal hypopigmentation or scarring (**D**)




FIG. 9. The beam setup and the dose distributions of treatment plans for multitarget using 4-box photon beam with multileaf collimator (PB), electron beam (EB), high-dose-rate (HDR) brachytherapy, intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT) are shown. The beam setup of PB (a), EB (e), HDR (i), IMRT (m), and VMAT (q) are shown. The axial dose distribution of PB (b), EB (f), HDR (j), IMRT (n), and VMAT (r) are shown. The sagittal dose distribution of PB (d), EB (h), HDR (l), IMRT (p), and VMAT (t), as well as the coronal dose distribution of PB (c), EB (g), HDR (k), IMRT (o), and VMAT (s), are also shown.

# Surface brachytherapy applications

- Uneven/complex surfaces
  - FF excellent for circumferential targets (So is VMAT – but VMAT will have higher exit doses)
- Tight conformality desired
  - Eg reirradiation
- Desire for superficial coverage only with importance of deeper structure dose sparing
- Some overlap with case selections between this, orthovoltage, etc
- Useful if centre has HDR capability without orthovoltage capability
  - More likely to encounter in US cancer centres than Canadian cancer centres
- Is this superior to IMRT/VMAT photon approach? Unclear

# Skin brachytherapy doses

**Table 2**
Different effective doses and fractionation for superficial brachytherapy.

| Author | Year | N. patients | N. Fractions | Dose per fraction | Total dose | Days per week | Fractions per day | Prescription | Applicator |
|---|---|---|---|---|---|---|---|---|---|
| Svoboda et al. [14] | 1995 | 130 | 1 | 20 Gy | 20 Gy | 1 | 1 | Surface | Mould |
| | | | 3 | 9–10 Gy | 27–30 Gy | 1 | 1 | Surface | Mould |
| | | | 10 | 4 Gy | 40 Gy | 5 | 1 | Surface | Mould |
| Guix et al. [17] | 2000 | 136 | 33–36 | 1.8 Gy | 59.4–64.8 Gy | 5 | 1 | 5 mm | Mould |
| Skowronek et al. [18] | 2005 | 179 | 5 | 10 Gy | 50 Gy | 1 | 1 | 5 mm | Mould/flap |
| | | | 12 | 5 Gy | 60 Gy | 2 | 1 | 5 mm | Mould/flap |
| Maroñas et al. [19] | 2011 | 51 | 11 or 12 | 4 Gy | 44–48 Gy | 3 | 1 | 3 mm | Mould/flap |
| | | | 18 | 3 Gy | 54 Gy | 3 | 1 | 3 mm | Mould |
| | | | 5 | 7 Gy | 35 Gy | 2 | 1 | 3 mm | Mould |
| Arenas et al. [28] | 2015 | 13 | 17 | 3 Gy | 51 Gy | 3 | 1 | 5 mm | Mould |
| Allan et al. [53] | 1998 | 28 | 8 | 5–5.5 Gy | 40–44 Gy | 5 | 2 | 2–3 mm | Mould |
| Rembielak | Unpublished data | | 8 | 4.7–5 Gy | 37.6–40 Gy | 4 | 2 | 5 mm | Mould |
| Arenas et al. [28] | 2015 | 101 | 15–19 | 3 Gy | 45–57 Gy | 3 | 1 | 3–5 mm | Leipzig |
| Köhler-Brock et al. [26] | 1999 | 520 | 8 | 5 Gy | 40 Gy | 2 | 1 | 6–8 mm | Leipzig |
| | | | 3 | 10 Gy | 30 Gy | 1 | 1 | 6–8 mm | Leipzig |
| Ghaly et al. [35] | 2008 | 67 | 8 | 5 Gy | 40 Gy | 2 | 1 | Variable | Leipzig |
| Gauden et al. [27] | 2013 | 236 | 12 | 3 Gy | 36 Gy | 5 | 1 | 3–4 mm | Leipzig |
| Tormo et al. [33] | 2014 | 78 | 6–7 | 6–7 Gy | 42 Gy | 2 | 1 | 3–4 mm | Valencia |
| Delishaj et al. [34] | 2015 | 84 | 8 | 5 Gy | 40 Gy | 2 or 3 | 1 | 3–4 mm | Valencia |

# More Skin brachytherapy doses

Table 2
Reported dose/fractionation regimens by treatment technique

| Technique[a] | |
|---|---|
| Electronic brachytherapy | 42 Gy/6 fractions |
| | 42 Gy/7 fractions |
| | 40 Gy/8 fractions |
| | Sensitive areas (e.g. face, lower extremity particularly anterior shin): |
| | 40–50 Gy/8–10 fractions |
| | 45–55 Gy/15–20 fractions |
| | 60–74 Gy/30–37 fractions |
| Radionuclide-based applicators | 42 Gy/6 fractions |
| | 42 Gy/7 fractions |
| | 40 Gy/8 fractions |
| | Sensitive areas: |
| | 40–50 Gy/8–10 fractions |
| | 44–54 Gy/15–18 fractions |
| Molds/flaps | 40–50 Gy/10–12 fractions |
| | 42 Gy/6 fractions |
| | 42 Gy/7 fractions |
| | Sensitive Areas: |
| | 60–70 Gy/30–35 fractions |
| | 55 Gy/20 fractions |
| | 40 Gy/10 fractions |
| | Postoperative: |
| | 35–40 Gy/10 fractions |
| | 40 Gy–45 Gy/8–9 fractions |
| | 42.5 Gy/17 fractions |
| | 60 Gy/20 fractions |
| | 30 Gy/10 fractions |
| Interstitial brachytherapy | 36–55 Gy/8–10 fractions |
| | Postoperative: |
| | 30–50 Gy/9–10 fractions |

# More reading

Radiotherapy and Oncology 126 (2018) 377–385

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

GEC-ESTRO ACROP Guideline

## GEC-ESTRO ACROP recommendations in skin brachytherapy

Jose L. Guinot [a], Agata Rembielak [b], Jose Perez-Calatayud [c], Silvia Rodríguez-Villalba [d], Janusz Skowronek [e,f], Luca Tagliaferri [g], Benjamin Guix [h], Victor Gonzalez-Perez [i], Vincenzo Valentini [g], György Kovacs [j], on behalf of the GEC ESTRO

[a] Department of Radiation Oncology, Foundation Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain; [b] Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; [c] Department of Radiation Oncology, La Fe University Hospital-IRIMED, Valencia, Spain; [d] Department of Radiation Oncology, Hospital Clinica Benidorm, Alicante, Spain; [e] Brachytherapy Department, Greater Poland Cancer Centre, Poznań, Poland; [f] Electroradiology Department, Poznan University of Medical Sciences, Poland; [g] Polo Scienze Oncologiche ed Ematologiche, Istituto di Radiologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy; [h] Department of Radiation Oncology, Foundation IMOR, Barcelona, Spain; [i] Department of Radiation Physics, Foundation Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain; [j] Interdisciplinary Brachytherapy Unit, UKSH CL, Lübeck, Germany

BRACHYTHERAPY

Brachytherapy 19 (2020) 415–426

ABS Consensus Statement

## The American Brachytherapy society consensus statement for skin brachytherapy

Chirag Shah [1,*], Zoubir Ouhib [2], Mitchell Kamrava [3], Shlomo A. Koyfman [1], Shauna R. Campbell [1], Ajay Bhatnagar [4], Joycelin Canavan [1], Zain Husain [5], Christopher A. Barker [6], Gil'ad N. Cohen [7], John Strasswimmer [8], Nikhil Joshi [1]

[1] Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
[2] Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL
[3] Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
[4] Department of Radiation Oncology, Alliance Oncology, Casa Grande, AZ
[5] Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
[6] Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
[7] Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
[8] College of Medicine (Dermatology) and College of Sciences (Biochemistry), Florida Atlantic University, Boca Raton, FL

# Combining beams

- Combining beam types can offer an advantage when planning difficult cases
- Leverages depth of photons, and dose fall-off particle therapies
- Patients referred to proton centres rare receive exclusively proton RT for entire treatment
  - Other reasons apart from technical advantage for this
- Downsides are the complexity of planning
- We will discuss opportunities where mixed beam approaches can add value
- Still an area of active research in treatment planning, medical physics community

# Orthovoltage Bump

*Journal of Radiation Research*, Vol. 59, No. 5, 2018, pp. 593–603
doi: 10.1093/jrr/rry045
Advance Access Publication: 25 June 2018

Journal of Radiation Research

OXFORD

## Radiation therapy for deep periocular cancer treatments when protons are unavailable: is combining electrons and orthovoltage therapy beneficial?

Kevin Martell[1,2,*,†], Yannick Poirier[3,†], Tiezhi Zhang[4], Alana Hudson[1,2], David Spencer[1,2], Ferenc Jacso[1,2], Richard Hayashi[2], Robyn Banerjee[1,2], Rao Khan[4], Nathan Wolfe[2] and Jon-Paul Voroney[1,2,†]

[1]Department of Oncology, University of Calgary, Tom Baker Cancer Centre 1331 29 Street Northwest, Calgary T2N 4N2, Alberta, Canada
[2]Calgary Zone, Alberta Health Services, Foothills Medical Centre, 1331-29 ST NW, Calgary, Alberta, Canada
[3]Department of Radiation Oncology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
[4]Department of Radiation Oncology, Washington University in St. Louis, 660 S. Euclid Ave., CB 8224, St. Louis, MO 63110, USA
*Corresponding author. Division of Radiation Oncology, University of Calgary, Tom Baker Cancer Centre 1331 29 Street Northwest, Calgary T2N 4N2, Alberta, Canada. Tel: +1-403-521-3378; Fax: +1-403-283-1651; Email: kevin.martell@albertahealthservices.ca
†Deceased
†Contributions from these authors were equal and they should be considered as co-first authors.
(Received 21 October 2017; revised 31 January 2018; editorial decision 3 May 2018)



**Fig. 2. Set-up for combination electrons with orthovoltage bump cases. Top: electron portion of treatment. Patients are immobilized within an Aquaplast shell; orbital shielding (only in medial canthus cases) is provided directly in the aperture. Bottom: orthovoltage therapy is performed with a tungsten eye shield in place and a custom lead cut-out.**




**Fig. 4. Isodose distributions for each case for electrons only, electrons with orthovoltage bump, volumetric-modulated arc therapy, conformal arc plans and proton therapy plans. Unless otherwise indicated, red, blue, green, magenta, beige and orange correspond to 95%, 90%, 80%, 70%, 50% and 30% isodose levels, respectively. Differences noted in image resolution are due to display differences between planning systems. OBE: electrons with orthovoltage bump; VMAT: volumetric-modulated arc therapy.**




**Fig. 3. PDD profiles by modality. Plotted are percentage depth–dose profiles for Case 1: retro-orbital melanoma; Case 2: large squamous cell carcinoma over superior eyelid; Case 3: medial canthus lesion number 1; and Case 4: second medial canthus lesion. Red, orange, green, blue and magenta colors correspond to plans for electron therapy, electrons with orthovoltage bump, volumetric-modulated arc therapy, conformal arc therapy and proton therapy, respectively.**




**Fig. 5. Planning target volume (PTV) dose–volume histogram (DVH) profiles by modality. Plotted are DVHs showing PTV coverage for Case 1: retro-orbital melanoma; Case 2: large squamous cell carcinoma over superior eyelid; Case 3: medial canthus lesion number 1; and Case 4: second medial canthus lesion. Red, orange, green, blue and magenta colors correspond to plans for electron therapy, electrons with orthovoltage bump, volumetric-modulated arc therapy, conformal arc therapy and proton therapy, respectively.**




**Fig. 6. Retinal dose–volume histogram (DVH) profiles by modality. Plotted are DVHs showing retinal dose for Case 1: retro-orbital melanoma; Case 2: large squamous cell carcinoma over superior eyelid; Case 3: medial canthus lesion number 1; and Case 4: second medial canthus lesion. Red, orange, green, blue and magenta colors correspond to plans for electron therapy, electrons with orthovoltage bump, volumetric-modulated arc therapy, conformal arc therapy and proton therapy, respectively.**

# Challenges with particle therapy planning

- Robustness is a challenge as soon as you start working with complex field arrangements
  - Particles like to ‘bounce around’
- Robustness optimization packages do exist for protons
- Methodologies exist at the research level for Mixed-Beam electron and photon optimization
  - Highly resource intensive to plan
  - But can be delivered on any standard linac
  - Can obliviate need to place bolus as can get adequate skin dose with electron contributions

# Why discuss novel techniques?

- Wish to highlight for you that the choice of modality here can greatly affect what DVH is possible for target and OAR
- Your ultimate choice will depend on what resources are available to you in practice
- Just remember, there is more possible than just VMAT

# Total skin electron therapy

- Really reserved for Mucosis Fungoides & Sézary Syndrome, few other (if any) indications
- COMPLEX
- Multiple techniques exist – suggest review article

Review paper

**Total skin electron irradiation techniques: a review**

**Tomasz Piotrowski[1,2], Piotr Milecki[1,3], Małgorzata Skórska[2], Dorota Fundowicz[4]**

[1]Department of Electroradiology, Poznan University of Medical Sciences, Poland
Head: Prof. Julian Malicki PhD
[2]Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland
Head: Prof. Julian Malicki PhD
[3]First Radiotherapy Department, Greater Poland Cancer Centre, Poznan, Poland
Head: Prof. Julian Malicki PhD
[4]Second Radiotherapy Department, Greater Poland Cancer Centre, Poznan, Poland
Head: Joanna Kaźmierska MD, PhD

Postep Derm Alergol 2013; XXX, 1: 50-55
DOI: 10.5114/pdia.2013.33379







**Figure 1** Stanford 6-field patient positioning (left) and TSEBT schedule (right). Right posterior oblique (RPO), anteroposterior (AP), and left posterior oblique (LPO) positions are treated on day 1. Right anterior oblique (RAO), posteroanterior (PA), and left anterior oblique (LAO) positions are treated on day 2. One fraction consists of day 1 and day 2 treatments. Two fractions are delivered per week. TSEBT, total skin electron beam therapy.




**Figure 2.** Positions of treatment apparatus gantry used to generate a dual field for the anterior body position in large-field TSEI [30]




**Figure 3.** Patient setup and geometric conditions of the single field rotation technique [58]

# Is TEST truly ‘Total’?

- There are areas that are undercovered, some of which are patient specific. Do not need to treat each of these for each patient, but requires a careful physical exam and if there is disease in the region, suggest boosting
- These are (but not limited to)
  - Scalp
  - Underneath pannus
  - Soles of feet
  - Perineum

# TEST is Toxic

- Doses are now shifting lower. Previously 30 Gy, now low dose regimens (eg 10-20 Gy) being evaluated and chosen more often, especially in context of evolving systemic therapy

Review Article



## Total skin electron beam therapy in mycosis fungoides—a shift towards lower dose?

**Mudit Chowdhary[1], Andrew Song[2], Nicholas G. Zaorsky[3], Wenyin Shi[2]**

[1]Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA; [2]Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA; [3]Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA

*Contributions:* (I) Conception and design: M Chowdhary, A Song, W Shi; (II) Administrative support: W Shi; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*Correspondence to:* Wenyin Shi, MD, PhD. Associate Professor, Department of Radiation Oncology, Thomas Jefferson University, 111 S. 11th St, Suite G301, Philadelphia, PA, USA. Email: Wenyin.shi@jefferson.edu.

# Merkel Cell Carcinoma

# Merkel Cell Carcinoma - Rare

- Rare - ~0.6/100 000 people/ year
- Canada – estimated 290 diagnoses/year

# Merkel Cell Carcinoma Genetics

- Merkel cell polyomavirus (MCV) detected in >80%
- MCV viral proteins bind to RB, interfering with TP53
- MCV neg – UV induced mutational inactivation of p53 and Tb, more mutations (prognosis ?worse)
- CK20- associated with MCV

# Merkel Cell Histology

- Cell of origin thought to be epidermal or dermal cell, rather than differentiated Merkel cell
  - ie not a tactile neuroendocrine epithelial cell (aka touch cell)
- One of those small round blue cell tumors



# Merkel Cell Presentation

- Rapidly enlarging, painless, red denuded nodule
- 65% local dz
- 25% regional
- 10% DM
- 20% have occult LN involvement, even if <2cm primary
- Ultimately DM in 50-60%
- Need PET staging and followup



**TABLE 19.2: AJCC 8th ed. (2017) Staging for Merkel Cell Carcinoma[6]**

| T/M \ N | | cN0 | cN1 | pN1a(sn) | pN1a | pN1b | c/pN2 | c/pN3 |
|---|---|---|---|---|---|---|---|---|
| **T1** | • ≤2 cm | **I** | **IIIA** | | | **IIIB** | | |
| **T2** | • 2.1–5 cm | **IIA** | | | | | | |
| **T3** | • >5 cm | | | | | | | |
| **T4** | • Invasion[1] | **IIB** | | | | | | |
| **M1a** | • Distant skin<br>• Subcutaneous tissue<br>• Distant LN | **IV** | | | | | | |
| **M1b** | • Lung | | | | | | | |
| **M1c** | • Any other visceral sites | | | | | | | |

*Major changes in the AJCC 8th Edition include delineation between clinical & pathologic N categories, new N2-N3 categories and updates to the prognostic staging groups.*

*Notes:* Invasion[1] = Invasion into fascia, cartilage, bone, or muscle.

cN1, metastasis in regional LN(s); pN1a(sn), clinically occult regional LN identified by sentinel lymph node biopsy only; pN1a, clinically occult regional LN following lymph node dissection; pN1b, clinically and/or radiologically detected regional LN with microscopic confirmation; c/pN2, in-transit metastasis (discontinuous from primary tumor, located between primary tumor and draining lymph node basin), without LN metastasis; c/pN3, in-transit metastasis with LN metastasis.

# Treatment

- WLE with 1-2cm margin
  - cN+ -> FNA
  - cN(-) -> SLNB
- LC 40-50% with Sx alone
  - 80% with adj RT






**Fig. 2.** Forrest plot for overall survival analysis.

# Risk factors for recurrence

- Thickness/DOI
- LVSI
- Infiltrative growth
- SLN status

# Adjuvant RT

- Recurrences recur early
  - Treat early, ideally w/in 4-6 weeks
- Could consider observation:
  - <1-2cm, widely excised, no LVI, not immunosuppressed

# Stage I MCC - Obs vs RT



Annals of Oncology

*Annals of Oncology* 23: 1074–1080, 2012
doi:10.1093/annonc/mdr318
Published online 12 July 2011

## Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study

T. Jouary[1]*, C. Leyral[1], B. Dreno[2], A. Doussau[3], B. Sassolas[4], M. Beylot-Barry[5], C. Renaud-Vilmer[6], B. Guillot[7], P. Bernard[8], C. Lok[9], C. Bedane[10], F. Cambazard[11], L. Misery[12], E. Estève[13], S. Dalac[14], L. Machet[15], F. Grange[16], P. Young[17], F. Granel-Brocard[18], F. Truchetet[19], B. Vergier[20], M. M. Delaunay[1] & J. J. Grob[21] for the Groupe de Cancérologie Cutanée of the Société Française de Dermatologie

[1]*Skin Cancer Unit, Dermatology Department, Hôpital Saint André, Bordeaux;* [2]*Department of Dermatology, Hôpital Hôtel Dieu, Nantes;* [3]*Bordeaux School of Public Health, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux 2, Bordeaux;* [4]*Department of Dermatology, Hôpital Morvan, Brest;* [5]*Department of Dermatology, Hôpital du Haut-Lévêque, Bordeaux Pessac;* [6]*Department of Dermatology, Hôpitaux Saint Louis et Saint Cloud, Paris;* [7]*Department of Dermatology, Hôpital Saint Eloi, Montpellier;* [8]*Department of Dermatology, Hôpital Robert Debré, Reims;* [9]*Department of Dermatology, Hôpital Sud, Amiens;* [10]*Department of Dermatology, Hôpital Dupuytren, Limoge;* [11]*Department of Dermatology, Hôpital Nord, Saint Etienne;* [12]*Department of Dermatology, Hôpital Edouard Herriot, Lyon;* [13]*Department of Dermatology, Hôpital Porte Madeleine, Orléans;* [14]*Department of Dermatology, Hôpital du Bocage, Dijon;* [15]*Department of Dermatology, Hôpital Trousseau, Tours;* [16]*Department of Dermatology, Hôpital Pasteur, Colmar;* [17]*Department of Dermatology, Hôpital Charles Nicolle, Rouen;* [18]*Department of Dermatology, Hôpital Fournier, Nancy;* [19]*Department of Dermatology, Hôpital Beauregard, Thionville;* [20]*Department of Pathology, Hôpital du Haut-Lévêque, Bordeaux Pessac;* [21]*Department of Dermatology, Hôpital Sainte-Marguerite, Marseille, France*

*Received 11 February 2011; revised 10 May 2011; accepted 12 May 2011*



# Stage I MCC – Obs vs RT

- Pretty damn good to have 100% regional control
- RT is effective – radiosensitive tumor




**Figure 3.** Regional recurrence probability according to the randomization group (group A: $n = 39$ patients; group B: $n = 44$ patients), $P = 0.007$. The group A curve intermingles with the abscises line as no patient experienced regional recurrence in this group.

# Treatment planning

- Cutaneous Oncology Group of French Society of Dermatology Guidelines (Boccara Eur J Derm 2012)
  - 50 Gy + 3cm margins +10 Gy boost to tumor bed
- CTV at least >=2cm in H&N
- CTV = 3-5cm elsewhere

- R0: 50-56 Gy
- R1: 56- 60 Gy
- R2 or gross nodes 60-66 Gy
- cN0 without nodal evaluation
  - 45 – 50 Gy
- Coverage of LNs for SLNB(-) or LND(-) is controversial

# Prognosis – Song, ASO 2020

- 50% stage I, 36% stage III
- MFU 3y
- Regional or DM in ~60%




**FIG. 4** Kaplan–Meier estimates of Merkel cell-specific survival

# Surface Anatomy – Dunn et al, British Journal of Plastic Surgery 1997




Fig. 1


7
14
6
13
5
11
8
10
1
9
12
3
4
18
2
5
6
15
16
17


20
16
21
17
22
18
28
25
24
27
23
19
26
8
7
F7
1
10
13
11
14
12
6
4
15
5
14
F10
2


8
16
17
13
18
14
19
12
11
20
1
2
3
15
9
23
4
21
10
22
5
6
24
7
8



# Good luck everyone

jordan.stosky@ahs.ca